# Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

> **NCT00087698** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 77 (actual)

## Conditions studied

- Pleural Neoplasms

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00087698
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2009-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087698, "Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00087698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*